Background
Methods
Reagents and antibodies
Tissue microarray
Immunohistochemisty (IHC)
HSCORE determination
In silicoanalysis of NILCO and targets interaction networks in breast cancer
Statistics
Results
Breast cancer tissue arrays
Breast cancer | Non-malignant | ||||
---|---|---|---|---|---|
Characteristic | ER- (n=21) | ER+(n=33) | TNBC (n=13) | P-value* | Hyperplasias (n=3) or Fibroadenomas (n=2) |
Age | 50.86 (± 12.47) | 48.67 (± 11.15) | 48.69 (± 11.6) | 0.778 | 34.2 (± 11.67) |
Grade | |||||
I | 0 (0) | 1 (3.03) | 0 (0) | 0.969 | NA |
II | 6 (28.57) | 10 (30.3) | 3 (23.08) | ||
III | 15 (71.43) | 22 (66.67) | 10 (76.92) | ||
Stage | |||||
1 | 1 (4.76) | 1 (3.03) | 0 (0) | 0.142 | NA |
2 | 17 (80.95) | 20 (60.61) | 5 (38.46) | ||
3 | 2 (9.52) | 7 (21.21) | 4 (30.77) | ||
4 | 1 (4.76) | 5 (15.15) | 4 (30.77) | ||
ER | |||||
Negative | 21 (100) | 0 (0) | 13 (100) |
<.001
| 2 (40) |
Positive | 0 (0) | 33 (100) | 0 (0) | 3 (60) | |
PR | |||||
Negative | 19 (90.48) | 11 (33.33) | 13 (100) |
<.001
| 2 (40) |
Positive | 2 (9.52) | 22 (66.67) | 0 (0) | 3 (60) | |
HER2 | |||||
Negative | 2 (9.52) | 12 (36.36) | 13 (100) |
<.001
| 5 (100) |
Positive | 19 (90.48) | 21 (63.64) | 0 (0) | NA | |
EGFR | |||||
Negative | 13 (61.9) | 31 (93.94) | 8 (61.54) |
0.004
| 5 (100) |
Positive | 8 (38.1) | 2 (6.06) | 5 (38.46) | NA | |
AR | |||||
Negative | 14 (66.67) | 13 (39.39) | 13 (100) |
<.001
| 3 (60) |
Positive | 7 (33.33) | 20 (60.61) | 0 (0) | 2 (40) | |
Ki67 | |||||
Negative | 8 (38.1) | 10 (30.3) | 5 (38.46) | 0.791 | 5 (100) |
Positive | 13 (61.9) | 23 (69.7) | 8 (61.54) | NA | |
P53 | |||||
Negative | 16 (76.19) | 24 (72.73) | 9 (69.23) | 0.903 | 5 (100) |
Positive | 5 (23.81) | 9 (27.27) | 4 (30.77) | NA |
Detection of NILCO and targets in breast cancer tissue arrays
Antigen | ER- (n=21) | ER+ (n=33) | TNBC (n=13) | P-value* |
---|---|---|---|---|
Notch1
| % positive | % positive | % positive | |
Nucleus | 90 | 97 | 83 | 0.0661 |
Cytoplasm | 90 | 97 | 92 | 0.2480 |
Stroma | 100 | 100 | 67 |
<.001
|
Notch4
| ||||
Nucleus | 74 | 74 | 42 |
0.0151
|
Cytoplasm | 90 | 77 | 50 | 0.0762 |
Stroma | 100 | 100 | 67 |
<.001
|
JAG1
| ||||
Nucleus | 84 | 77 | 50 |
0.0281
|
Cytoplasm | 90 | 88 | 75 | 0.0694 |
Stroma | 100 | 100 | 100 | - |
DLL4
| ||||
Nucleus | 90 | 88 | 100 | 0.098 |
Cytoplasm | 90 | 88 | 100 | 0.098 |
Stroma | 0 | 0 | 0 | - |
Leptin
| ||||
Cytoplasm | 68 | 65 | 100 |
<.001
|
Stroma | 68 | 59 | 67 | 0.4055 |
OB-R
| ||||
Cytoplasm | 84 | 71 | 67 | 0.3023 |
Stroma | 84 | 79 | 83 | 0.3311 |
IL-1R tI
| ||||
Cytoplasm | 90 | 97 | 83 | 0.3867 |
Stroma | 100 | 100 | 83 | 0.2736 |
VEGF
| ||||
Nucleus | 58 | 94 | 92 | 0.4221 |
Cytoplasm | 100 | 91 | 92 | 0.4414 |
Stroma | 91 | 100 | 100 | - |
VEGFR2
| ||||
Nucleus | 84 | 85 | 50 | 0.0901 |
Cytoplasm | 90 | 85 | 75 | 0.2668 |
Stroma | 32 | 35 | 100 |
<.001
|
Associations of HSCOREs of NILCO and targets with breast cancer type
Breast cancer | Non-malignant | ||||
---|---|---|---|---|---|
Antigen | ER- (n=21) | ER+ (n=33) | TNBC (n=13) | P-value* | Hyperplasias (n=3) or Fibroadenomas(n=2) |
Notch1
| 2.6 (2.01-3.19) | 2.55 (1.9-3.19) | 2.43 (1.68-3.18) | 0.743 | 1.45 (1.04-1.86) |
Negative | 0 (0) | 0 (0) | 1 (7.69) | 0.194 | NA |
Positive | 21 (100) | 33 (100) | 12 (92.31) | 5 (100) | |
Notch4
| 1.67 (1–3.48) | 1.62 (1–2.9) | 1.36 (1–2.87) | 0.449 | 2 (1.23 - 2) |
Negative | 5 (25) | 5 (16.13) | 5 (41.67) | 0.204 | NA |
Positive | 15 (75) | 26 (83.87) | 7 (58.33) | 3 (100) | |
JAG1
| 1.23 (1–2.09) | 1.37 (1–3) | 1.23 (1–2.24) | 0.776 | 1.28 (1.11 - 2.28) |
Negative | 6 (28.57) | 9 (27.27) | 4 (30.77) | 0.972 | NA |
Positive | 15 (71.43) | 24 (72.73) | 9 (69.23) | 5 (100) | |
DLL4
| 3.16 (1.91 - 3.66) | 3.21 (2–3.87) | 2.85 (1.19 - 3.36) |
0.028
| 3.18 (2.59 - 3.68) |
Negative | NA | NA | NA | NA | NA |
Positive | 21 (100) | 33 (100) | 13 (100) | 5 (100) | |
Leptin
| 2.69 (1–4) | 3.16 (1–4) | 1.5 (1–3.84) | 0.675 | 1 (1–1.24) |
Negative | 6 (28.57) | 10 (30.3) | 5 (38.46) | 0.820 | 3 (60) |
Positive | 15 (71.43) | 23 (69.7) | 8 (61.54) | 2 (40) | |
OB-R
| 1.06 (1–2.3) | 1.11 (1–2.2) | 1.05 (1–2.27) | 0.924 | 1 (1–1.5) |
Negative | 7 (33.33) | 10 (30.3) | 5 (38.46) | 0.867 | 4 (80) |
Positive | 14 (66.67) | 23 (69.7) | 8 (61.54) | 1 (20) | |
IL-1R tI
| 3.65 (2.55 - 4) | 3.72 (2.46 - 4) | 3.31 (1–4) |
0.027
| 3.99 (2.74 - 4) |
Negative | 7 (33.33) | 10 (30.3) | 5 (38.46) | 0.194 | NA |
Positive | 14 (66.67) | 23 (69.7) | 8 (61.54) | 4 (100) | |
VEGF
| 3.74 (2.22 - 4) | 3.67 (2.64 - 4) | 3.77 (1.04 - 4) | 0.767 | 3.96 (3.74 - 4) |
Negative | NA | NA | NA | NA | NA |
Positive | 21 (100) | 33 (100) | 13 (100) | 5 (100) | |
VEGFR2
| 1 (1–2) | 1 (1–2) | 1 (1–2) | 0.506 | 1 (1–1.1) |
Negative | 15 (71.43) | 20 (60.61) | 9 (69.23) | 0.685 | 3 (60) |
Positive | 6 (28.57) | 13 (39.39) | 4 (30.77) | 2 (40) |
Correlations of NILCO and targets in breast cancer
Notch1 | |||||||||
---|---|---|---|---|---|---|---|---|---|
Notch1
| 1.000 |
Notch4
| |||||||
Notch4
| 0.132 (0.303) | 1.000 | |||||||
JAG1
| |||||||||
JAG1
| -0.128 (0.302) | -0.181 (0.155) | 1.000 | ||||||
DLL4
| |||||||||
DLL4
| -0.053 (0.672) | 0.247 (0.051)
| 0.096 (0.441) | 1.000 | |||||
Leptin
| |||||||||
Leptin
| 0.055 (0.659) | -0.267 (0.035)
| 0.337 (0.005)
| 0.157 (0.206) | 1.000 | ||||
OB-R
| |||||||||
OB-R
| 0.098 (0.428) | 0.026 (0.841) | 0.288 (0.018)
| 0.228 (0.064) | 0.359 (0.002)
| 1.000 | |||
IL-1R tI
| |||||||||
IL-1R tI
| 0.407 (0.001)
| 0.003 (0.985) | -0.024 (0.848) | 0.087 (0.484) | 0.221 (0.073) | 0.153 (0.218) | 1.000 | ||
VEGF
| |||||||||
VEGF
| -0.137 (0.269) | -0.083 (0.517) | 0.243 (0.047)
| 0.298 (0.014)
| 0.461 (<.001)
| 0.278 (0.023)
| 0.025 (0.844) | 1.000 | |
VEGFR2
| |||||||||
VEGFR2
| 0.023 (0.852) | 0.279 (0.027)
| -0.132 (0.289) | 0.057 (0.646) | -0.370 (0.002)
| -0.001 (0.992) | 0.044 (0.725) | -0.176 (0.154) | 1.000 |
Associations of A_HSCOREs of NILCO and targets with EGFR, AR, Ki67 and p53 expression
EGFR | AR | |||||
---|---|---|---|---|---|---|
Antigen | Negative (N=52) | Positive (N=15) | P-value* | Negative (N=40) | Positive (N=27) | P-value* |
Notch1
| 2.44 (1.78- 3.06) | 2.89 (2.28-3.50) |
0.018
| 2.49 (1.84-3.09) | 2.62 (1.99-3.25) | 0.403 |
Negative | 1 (1.92) | 0 (0) | 1.000 | 1 (2.5) | 0 (0) | 1.000 |
Positive | 51 (98.08) | 15 (100) | 39 (97.5) | 27 (100) | ||
Notch4
| 1.55 (1–3.48) | 1.81 (1–2.5) | 0.782 | 1.62 (1–3.48) | 1.7 (1–2.5) | 0.966 |
Negative | 12 (25) | 3 (20) | 1.000 | 10 (27.03) | 5 (19.23) | 0.474 |
Positive | 36 (75) | 12 (80) | 27 (72.97) | 21 (80.77) | ||
JAG1
| 1.35 (1–3) | 1.17 (1–2.09) | 0.215 | 1.28 (1–2.43) | 1.23 (1–3) | 0.510 |
Negative | 13 (25) | 6 (40) | 0.332 | 13 (32.5) | 6 (22.22) | 0.360 |
Positive | 39 (75) | 9 (60) | 27 (67.5) | 21 (77.78) | ||
DLL4
| 3.15 (1.91 - 3.87) | 3.27 (1.19 - 3.66) | 0.443 | 3.19 (1.19 - 3.65) | 3.15 (2–3.87) | 0.828 |
Negative | NA | NA | NA | NA | NA | NA |
Positive | 52 (100) | 15 (100) | 40 (100) | 27 (100) | ||
Leptin
| 3.07 (1–4) | 2.69 (1–4) | 0.825 | 2.88 (1–4) | 3.02 (1–4) | 0.938 |
Negative | 16 (30.77) | 5 (33.33) | 1.000 | 12 (30) | 9 (33.33) | 0.773 |
Positive | 36 (69.23) | 10 (66.67) | 28 (70) | 18 (66.67) | ||
OB-R
| 1.09 (1–2.3) | 1.05 (1–1.26) | 0.338 | 1.1 (1–2.27) | 1.06 (1–2.3) | 0.359 |
Negative | 17 (32.69) | 5 (33.33) | 1.000 | 12 (30) | 10 (37.04) | 0.547 |
Positive | 35 (67.31) | 10 (66.67) | 28 (70) | 17 (62.96) | ||
IL-1R tI
| 3.67 (1–4) | 3.52 (1.56 - 4) | 0.255 | 3.53 (1–4) | 3.86 (2.46 - 4) |
0.026
|
Negative | 1 (1.92) | 0 (0) | 1.000 | 1 (2.5) | 0 (0) | 1.000 |
Positive | 51 (98.08) | 15 (100) | 39 (97.5) | 27 (100) | ||
VEGF
| 3.64 (1.04 - 4) | 3.81 (2.45 - 4) | 0.625 | 3.67 (1.04 - 4) | 3.74 (2.83 - 4) | 0.635 |
Negative | NA | NA | NA | NA | NA | NA |
Positive | 52 (100) | 15 (100) | 40 (100) | 27 (100) | ||
VEGFR2
| 1 (1–2) | 1 (1–2) | 0.957 | 1 (1–2) | 1 (1–2) | 0.757 |
Negative | 34 (65.38) | 10 (66.67) | 0.927 | 27 (67.5) | 17 (62.96) | 0.701 |
Positive | 18 (34.62) | 5 (33.33) | 13 (32.5) | 10 (37.04) |
Ki67 | p53 | |||||
---|---|---|---|---|---|---|
Antigen | Negative (n=52) | Positive (n=15) | P-value* | Negative (n=40) | Positive (n=27) | P-value* |
Notch1
| 2.27(1.68-2.86) | 2.69 (2.06-3.32) |
0.010
| 2.51(1.82-3.20) | 2.63 (2.13-3.13) | 0.528 |
Negative | 1 (4.35) | 0 (0) | 0.343 | 1 (2.04) | 0 (0) | 1.000 |
Positive | 22 (95.65) | 44 (100) | 48 (97.96) | 18 (100) | ||
Notch4
| 1.42 (1–2.82) | 1.69 (1–3.48) | 0.125 | 1.51 (1–3.48) | 1.8 (1–2.87) | 0.404 |
Negative | 7 (33.33) | 8 (19.05) | 0.209 | 12 (26.67) | 3 (16.67) | 0.522 |
Positive | 14 (66.67) | 34 (80.95) | 33 (73.33) | 15 (83.33) | ||
JAG1
| 1.37 (1–2.24) | 1.21 (1–3) | 0.350 | 1.2 (1–3) | 1.54 (1–2.43) | 0.587 |
Negative | 3 (13.04) | 16 (36.36) |
0.044
| 14 (28.57) | 5 (27.78) | 0.949 |
Positive | 20 (86.96) | 28 (63.64) | 35 (71.43) | 13 (72.22) | ||
DLL4
| 3.21 (1.91 - 3.66) | 3.11 (1.19 - 3.87) | 0.584 | 3.15 (1.19 - 3.66) | 3.21 (2.59 - 3.87) | 0.651 |
Negative | NA | NA | NA | NA | NA | NA |
Positive | 23 (100) | 44 (100) | 49 (100) | 18 (100) | ||
Leptin
| 3.34 (1–4) | 2.66 (1–4) | 0.841 | 2.64 (1–4) | 3.29 (1–4) | 0.541 |
Negative | 7 (30.43) | 14 (31.82) | 0.908 | 16 (32.65) | 5 (27.78) | 0.703 |
Positive | 16 (69.57) | 30 (68.18) | 33 (67.35) | 13 (72.22) | ||
OB-R
| 1.08 (1–2.27) | 1.07 (1–2.3) | 0.648 | 1.08 (1–2.3) | 1.11 (1–2.2) | 0.666 |
Negative | 7 (30.43) | 15 (34.09) | 0.762 | 17 (34.69) | 5 (27.78) | 0.593 |
Positive | 16 (69.57) | 29 (65.91) | 32 (65.31) | 13 (72.22) | ||
IL-1R tI
| 3.63 (1–4) | 3.63 (1.56 - 4) | 0.714 | 3.65 (1–4) | 3.55 (2.62 - 4) | 0.847 |
Negative | 1(4.35) | 0 (0) | 0.343 | 1 (2.04) | 0 (0) | 1.000 |
Positive | 22(95.65) | 44(100) | 48(97.96) | 18(100) | ||
VEGF
| 4(1.04 - 4) | 3.56(2.22 - 4) | 0.056 | 2.51(± 0.69) | 2.63(± 0.5) | 0.528 |
Negative | NA | NA | NA | 1(2.04) | 0(0) | 1.000 |
Positive | 23(100) | 44(100) | 48(97.96) | 18(100) | ||
VEGFR2
| 1.09(1–2) | 1(1–2) |
0.047
| 1.51(1–3.48) | 1.8(1–2.87) | 0.404 |
Negative | 11(47.83) | 33(75) |
0.026
| 12(26.67) | 3(16.67) | 0.522 |
Positive | 12(52.17) | 11(25) | 33(73.33) | 15 (83.33) |